PTGS2 and Alzheimer disease: Studies have suggested that PPAR-γ agonists may have therapeutic potential in AD by reducing the expression of COX-2 and decreasing the neuroinflammatory response (Chen et al., 2012, Bordet et al., 2006; Kapadia et al., 2008; Lastra et al., 2004).